Results of a Phase II Study of Palbociclib in Esophageal and Gastric Cancer
Thomas Karasic, MD, investigator at Penn Medicine, discusses a phase II trial of palbociclib (Ibrance) in patients with advanced <br /> esophageal or gastric cancer.<br />